P3 Health Partners (PIII) Competitors $7.48 +0.17 (+2.25%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PIII vs. DCGO, CORBF, NAKA, EUDA, QIPT, SERA, KDLY, BNR, ATPC, and BDSXShould you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include DocGo (DCGO), Global Cord Blood (CORBF), KindlyMD (NAKA), EUDA Health (EUDA), Quipt Home Medical (QIPT), Sera Prognostics (SERA), Kindly MD (KDLY), Burning Rock Biotech (BNR), Agape ATP (ATPC), and Biodesix (BDSX). These companies are all part of the "healthcare" industry. P3 Health Partners vs. Its Competitors DocGo Global Cord Blood KindlyMD EUDA Health Quipt Home Medical Sera Prognostics Kindly MD Burning Rock Biotech Agape ATP Biodesix DocGo (NASDAQ:DCGO) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk. Do analysts rate DCGO or PIII? DocGo presently has a consensus price target of $3.59, indicating a potential upside of 122.29%. P3 Health Partners has a consensus price target of $16.25, indicating a potential upside of 117.10%. Given DocGo's higher possible upside, equities analysts plainly believe DocGo is more favorable than P3 Health Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50P3 Health Partners 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is DCGO or PIII more profitable? DocGo has a net margin of -4.20% compared to P3 Health Partners' net margin of -9.99%. DocGo's return on equity of -3.26% beat P3 Health Partners' return on equity.Company Net Margins Return on Equity Return on Assets DocGo-4.20% -3.26% -2.24% P3 Health Partners -9.99%-183.60%-17.83% Do institutionals & insiders believe in DCGO or PIII? 56.4% of DocGo shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 3.8% of DocGo shares are owned by company insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, DCGO or PIII? DocGo has higher earnings, but lower revenue than P3 Health Partners. DocGo is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDocGo$616.55M0.26$19.99M-$0.19-8.50P3 Health Partners$1.50B0.04-$135.85M-$46.01-0.16 Which has more volatility & risk, DCGO or PIII? DocGo has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Does the media refer more to DCGO or PIII? In the previous week, P3 Health Partners had 3 more articles in the media than DocGo. MarketBeat recorded 8 mentions for P3 Health Partners and 5 mentions for DocGo. DocGo's average media sentiment score of 0.27 beat P3 Health Partners' score of -0.10 indicating that DocGo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral P3 Health Partners 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDocGo beats P3 Health Partners on 11 of the 15 factors compared between the two stocks. Get P3 Health Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PIII vs. The Competition Export to ExcelMetricP3 Health PartnersMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.82M$2.09B$5.75B$9.56BDividend YieldN/AN/A4.53%4.07%P/E Ratio-0.1637.5630.4425.14Price / Sales0.049.76391.6287.40Price / CashN/A50.4237.0358.50Price / Book1.216.519.006.20Net Income-$135.85M-$63.67M$3.26B$265.38M7 Day Performance7.85%1.20%1.00%-1.13%1 Month Performance12.56%0.67%4.23%-0.70%1 Year Performance-71.42%21.98%28.45%18.99% P3 Health Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PIIIP3 Health Partners1.8039 of 5 stars$7.49+2.3%$16.25+117.1%-72.4%$53.82M$1.50B-0.16500Earnings ReportShort Interest ↑Analyst RevisionDCGODocGo2.1405 of 5 stars$1.68+3.7%$3.56+111.9%-54.3%$158.45M$616.55M-8.844,407Analyst ForecastCORBFGlobal Cord BloodN/A$1.25+127.3%N/A-14.3%$151.94M$196.12M0.001,200NAKAKindlyMDN/A$12.02-12.1%N/AN/A$103.17M$2.72M-13.98N/AEUDAEUDA Health0.7685 of 5 stars$2.64+3.9%N/A-54.5%$94.38M$4.01M0.002Gap UpQIPTQuipt Home Medical3.3134 of 5 stars$2.26+10.8%$2.85+26.1%-17.0%$88.63M$245.91M-9.421,200Analyst ForecastSERASera Prognostics0.8214 of 5 stars$2.38+5.8%N/A-68.1%$84.76M$80K-2.80120News CoverageKDLYKindly MDN/A$13.67-9.0%N/A+519.5%$82.32M$2.47M-17.75N/ANews CoveragePositive NewsGap DownBNRBurning Rock Biotech0.3676 of 5 stars$10.17+36.0%N/A+40.9%$80.50M$70.67M-5.381,390News CoverageUpcoming EarningsGap DownHigh Trading VolumeATPCAgape ATP0.0939 of 5 stars$1.31+4.0%N/A-36.1%$63.01M$1.32M-3.2040News CoverageShort Interest ↑BDSXBiodesix3.1274 of 5 stars$0.43+7.2%$1.75+311.8%-76.4%$58.11M$71.32M-1.47220 Related Companies and Tools Related Companies DCGO Competitors CORBF Competitors NAKA Competitors EUDA Competitors QIPT Competitors SERA Competitors KDLY Competitors BNR Competitors ATPC Competitors BDSX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PIII) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding P3 Health Partners Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share P3 Health Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access